RARE News and Press, Ultragenyx Pharmaceutical Inc. From 04/12/24

NOVATO, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that preclinical and clinical data, including new clinical efficacy and safety data from the expansion cohorts in the Phase 1/2 study of GTX-102 for the treatment of Angelman syndrome,...

2024-03-28 13:46:05 ET More on Invesco S&P 500 Equal Weight ETF: RSP: Equal Weighting The S&P 500 To Minimize Magnificent Seven Exposure Is Not Optimal RSP: I Firmly Believe In An Allocation To Equal-Weight At This Juncture RSP: Happy 2024! Don't Make Decisio...

2024-03-18 11:30:02 ET Wedbush analyst issues BUY recommendation for RARE on March 18, 2024 09:00AM ET. The previous analyst recommendation was Buy. RARE was trading at $47.78 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...

2024-03-11 11:53:40 ET Summary Positive interim results released from phase 1/2 AFFINITY study, using RGX-202 for the treatment of patients with Duchenne Muscular Dystrophy. Functional and strength data from the phase 1/2 AFFINITY study, using RGX-202 for the treatment of patients...

2024-03-09 09:55:42 ET Summary Ultragenyx's stock has increased by approximately 9% but lags behind the S&P's return of 28%. The article assesses Ultragenyx's current merits per its recently reported Q4, 2023 earnings as we progress into 2024. The previous "Sell" rating ba...

2024-03-06 17:09:23 ET Summary Baker Brothers' 13F portfolio value decreased from $17.35B to $8.79B. The largest five stakes in the portfolio are Incyte, BeiGene, ACADIA Pharma, Madrigal Pharma, and Rhythm Pharma. New stakes include Cerevel Therapeutics, while stake disposals ...

44 th Annual Cowen Healthcare Conference on March 4 Leerink Partners Global Biopharma Conference on March 12 Barclays 26 th Annual Global Healthcare Conference on March 13 NOVATO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) --  Ultragenyx Pharmaceut...

2024-02-23 01:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-02-15 23:55:23 ET Call End: Ultragenyx Pharmaceutical, Inc. (RARE) Q4 2023 Earnings Conference Call February 15, 2024, 05:00 PM ET Company Participants Joshua Higa - Vice President of Investor Relations Emil Kakkis - Chief Executive Officer & President ...

2024-02-15 16:02:14 ET More on Ultragenyx Pharmaceutical A Deeper Look At Ultragenyx Pharmaceutical DOJ says Ultragenyx to pay $6M to resolve Medicare claims allegations Wells Fargo starts Ultragenyx coverage with overweight rating Seeking Alpha’s Quan...